Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles,

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls significantly when they learn that the weight might come back when the meds are stopped.

According to that study, those who use GLP-1 dugs, such as Wegovy and Ozempic, cut their grocery spend by about 6% during the first few months after starting their prescription, translating to $416 annually. The impact is even greater in higher-income households earning over $125,000, who reduce their grocery spending by 9%, or $690, annually.

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

Indiana’s Medicaid program estimates the Biden administration’s proposal to expand coverage of weight-loss treatment for people with obesity could cost it up to $70 million a year, covering up to 20% of eligible enrollees.

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts weigh the pros and cons of the practice.